NATCO applies to CDSCO for EUA of Molnupiravir capsules

Pre-clinical data have shown that Molnupiravir has broad anti-influenza activity, including highly potent inhibition of SARS-CoV-2 replication.

65
CDSCO FDA

Natco Pharma has applied to the Central Drugs Standard Control Organization (CDSCO) in India for approval of Phase-III clinical trial of Molnupiravir Capsules for the treatment of C-19 positive patients.

Pre-clinical data have shown that Molnupiravir has broad anti-influenza activity, including highly potent inhibition of SARS-CoV-2 replication.


To read more articles on Natco Pharma, click here


Patients treated with Molnupiravir achieved response within five days of therapy indicating that the duration of treatment with Molnupiravir is short, with the additional advantage of being an oral therapy.

Medicine Capsule
Picture: Pixabay

NATCO is hoping that CDSCO would give emergency approval of this drug based on “compassionate use” for patients. “Compassionate use” approval is given for investigational drugs so a patient with an immediately life-threatening condition can gain access to the drug.

The company is ready to launch the product this month if approval is given.


Also read:

Bharat Biotech seeks DCGI’s nod to extend shelf life of Covaxin

IISER develops affordable Oxygen Concentrator

4 arrested for black marketing Remdesivir Injection

Lupin, Sun, Jubilant recall generic medicines in US

Govt exempts customs duty on C-19 vaccine, Oxygen and related equipment

Pharma firms ramp up Remdesivir output


Enter your email address:

Delivered by FeedBurner

Latest updates

The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.

Go to main website, click here

Follow and connect with us on Facebook and Linkedin

For daily free updates on WhatsApp, click here

Subscribe here for daily updates
Loading